Novel Immunotoxin MT-5111 in Avoiding Competition With & Overcoming the Primary Mechanisms of Tumor Resistance to Current HER2-Targeted Therapies

Time: 11:30 am
day: Day Two


• Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers
• Discussing potential indications
• Discussing the biomarker and patient status
• Latest data and future directions